<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745340</url>
  </required_header>
  <id_info>
    <org_study_id>344/15s</org_study_id>
    <nct_id>NCT02745340</nct_id>
  </id_info>
  <brief_title>Substitution of Acetate by Citrate in the Bicarbonate Based Hemodialysis</brief_title>
  <official_title>Effect of an Acetate-free Dialysis (Citrate Based) on Parameters of Central Hemodynamics, Dialysis Adequacy, Quality of Life and Immunological Parameters in Chronic Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gambro Renal Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acetate is the primary acidifying solution used in bicarbonate-based hemodialysis worldwide.
      It has been published in small trials or case series that the addition of acetate is
      associated with a rise in nitric oxide production of vascular smooth muscle cells,
      endothelial cells and myocardial cells as a sign of vascular dysfunction. Furthermore
      clinical side effects of dialysis e.g. nausea, malnutrition, intradialytic blood pressure
      drops, induction of proinflammatory cytokines and activation of complement and leukocytes
      have been described with acetate.

      Citrate on the other hand was associated with: Acid-base disorders (metabolic alkalosis),
      Disturbances of the calcium homeostasis (Hypocalcemia), but also anti-inflammatory effects.
      Both dialysate additives (citrate and acetate) are commercially available and are used world
      wide in dialysis centers.

      The investigators hypothesize that substitution of acetate by citrate reduces the
      cardiovascular risk (measured by a change in the surrogate parameter of pulse wave velocity
      and Augmentation index) and might improves quality of life in the participants. Furthermore
      the investigators speculate that citrate in the dialysis solution could reduce systemic
      inflammation in the participants of the study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Augmentation Index (AIx)</measure>
    <time_frame>6 months (cross over after 3 months)</time_frame>
    <description>cross over design</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <arm_group>
    <arm_group_label>Acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acetate by Citrate substitution and vice versa</intervention_name>
    <description>substitution of acetate by citrate in dialysis fluid</description>
    <arm_group_label>Acetate</arm_group_label>
    <arm_group_label>Citrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  time since initiation of dialysis &gt; 3 months

          -  age &gt; 18 years

          -  dialysis 3x/week for &gt; 4 hrs

        Exclusion Criteria:

          -  ongoing infection

          -  pregnancy

          -  lack of written and informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Schmaderer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>attending, board certified nephrologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Schmaderer, M.D.</last_name>
    <phone>0049-89-4140</phone>
    <phone_ext>5053</phone_ext>
    <email>christoph.schmaderer@mri.tum.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nierenzentrum24 NEUPERLACH</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Maceiczyk, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Carla Maceizyk, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nierenzentrum Bogenhausen</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Bieber, M.D.</last_name>
      <phone>0049 89 4522380</phone>
    </contact>
    <investigator>
      <last_name>Richard Bieber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Molina Nuñez M, de Alarcón R, Roca S, Álvarez G, Ros MS, Jimeno C, Bucalo L, Villegas I, García MÁ. Citrate versus acetate-based dialysate in on-line haemodiafiltration. A prospective cross-over study. Blood Purif. 2015;39(1-3):181-7.</citation>
    <PMID>25791278</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität München</investigator_affiliation>
    <investigator_full_name>PD Dr. Christoph Schmaderer</investigator_full_name>
    <investigator_title>Study Principal Investigator (Prüfer)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

